Epirubicin
Information
- Drug Name
- Epirubicin
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| breast cancer | PIK3CA MUTATION PIK3CA MUTATION | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 18371219 | Detail |
| breast cancer | FOXP3 EXPRESSION FOXP3 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 22431701 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| This study of 140 patients with stage II-III breas... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | false | CIViC Evidence | detail |
| 1,097 patients with breast cancer were evaluated f... | FOXP3 | FOXP3 EXPRESSION FOXP3 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04770272 | Active, not recruiting | Phase 2 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy | March 1, 2021 | August 31, 2024 |
| NCT04214626 | Active, not recruiting | Phase 2 | R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma | January 2, 2020 | January 2, 2025 |
| NCT01779206 | Active, not recruiting | Phase 2/Phase 3 | ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer | May 2012 | October 2024 |
| NCT04172259 | Active, not recruiting | Phase 2 | ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | January 10, 2019 | September 30, 2026 |
| NCT01358877 | Active, not recruiting | Phase 3 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | November 8, 2011 | November 28, 2024 |
| NCT03036488 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | March 7, 2017 | September 30, 2025 |
| NCT02752815 | Active, not recruiting | Phase 4 | Reduced Chemotherapy in Low Risk DLBCL | June 14, 2016 | December 31, 2024 |
| NCT00154739 | Completed | Phase 2 | Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC) | October 1998 | July 2005 |
| NCT00193050 | Completed | Phase 2 | Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer | November 2001 | March 2009 |
| NCT00193206 | Completed | Phase 2 | Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | September 2005 | May 2009 |
| NCT00215514 | Completed | Early Phase 1 | Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma | September 2000 | July 2014 |
| NCT00215644 | Completed | Phase 2 | Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer | August 31, 2005 | August 31, 2008 |
| NCT00231582 | Completed | Phase 2 | High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II | September 2004 | January 2010 |
| NCT00242203 | Completed | Phase 2 | Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer | October 2002 | May 2011 |
| NCT00246103 | Completed | Phase 1 | Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies | March 2004 | April 2008 |
| NCT00270894 | Completed | Phase 2 | Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients | November 2005 | August 2011 |
| NCT00309556 | Completed | Phase 3 | Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer | February 2005 | November 2011 |
| NCT00309569 | Completed | Phase 3 | Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients | October 1991 | September 2000 |
| NCT00322374 | Completed | Phase 1 | Phase I Combination w/ Epirubicin | August 2006 | February 2009 |
| NCT00336791 | Completed | Phase 3 | Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer | September 2003 | September 2010 |
| NCT00424606 | Completed | Phase 3 | Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients | June 2001 | August 2013 |
| NCT00425516 | Completed | Phase 2 | Breast Cancer Treated by Neoadjuvant Chemotherapy | January 2007 | August 2014 |
| NCT00429871 | Completed | Phase 3 | Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer | May 2002 | November 2007 |
| NCT00431080 | Completed | Phase 3 | Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | August 2004 | October 2007 |
| NCT00432172 | Completed | Phase 2 | Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | April 24, 2007 | September 1, 2010 |
| NCT00454636 | Completed | Phase 2 | A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. | March 2007 | July 2010 |
| NCT00464646 | Completed | Phase 2 | Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer | May 2007 | May 2014 |
| NCT00038402 | Completed | Phase 3 | Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer | April 2001 | July 2011 |
| NCT00054587 | Completed | Phase 3 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | June 2001 | December 2009 |
| NCT00087178 | Completed | Phase 3 | Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer | May 2004 | May 2016 |
| NCT00123318 | Completed | Phase 3 | A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer | February 2003 | February 2012 |
| NCT00129922 | Completed | Phase 3 | Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer | November 1999 | December 2007 |
| NCT00129935 | Completed | Phase 3 | EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer | February 2004 | April 4, 2019 |
| NCT00146588 | Completed | N/A | Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer | April 2002 | December 2004 |
| NCT00540800 | Completed | Phase 3 | BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer | February 2004 | December 2009 |
| NCT00556127 | Completed | Phase 2 | Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | June 2002 | September 2006 |
| NCT00615602 | Completed | Phase 3 | Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer | October 2004 | May 2012 |
| NCT00705315 | Completed | Phase 1/Phase 2 | Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer | May 2008 | June 2010 |
| NCT00719550 | Completed | Phase 1/Phase 2 | AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer | February 2009 | June 2013 |
| NCT00722293 | Completed | Phase 1 | A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | July 8, 2008 | February 25, 2014 |
| NCT00743964 | Completed | Phase 2 | Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC) | April 2008 | October 2009 |
| NCT00841828 | Completed | Phase 2 | Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | February 2009 | December 2013 |
| NCT00950300 | Completed | Phase 3 | A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer | October 16, 2009 | January 24, 2017 |
| NCT01026116 | Completed | Phase 3 | A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old | December 2009 | December 23, 2016 |
| NCT01036087 | Completed | Phase 2 | Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer | November 2010 | August 9, 2022 |
| NCT01049425 | Completed | Phase 3 | Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer | February 5, 2009 | May 15, 2018 |
| NCT01148446 | Completed | Phase 3 | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | January 2003 | |
| NCT01150630 | Completed | Phase 2 | Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer | May 2010 | August 2017 |
| NCT01216644 | Completed | Phase 2/Phase 3 | 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer | August 2010 | May 2019 |
| NCT01386346 | Completed | Phase 1 | Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer | June 2011 | September 2018 |
| NCT01433614 | Completed | Phase 3 | Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer | December 2002 | December 2013 |
| NCT01593020 | Completed | Phase 2 | Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | August 3, 2012 | November 4, 2020 |
| NCT01594177 | Completed | Phase 2 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy | May 2012 | March 2014 |
| NCT01630083 | Completed | Phase 2 | Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer | July 19, 2012 | January 31, 2019 |
| NCT01690702 | Completed | Phase 3 | Study of Nab-Paclitaxel in High Risk Early Breast Cancer | September 2012 | July 20, 2020 |
| NCT01710592 | Completed | Phase 2 | A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer | May 2007 | |
| NCT01726452 | Completed | Phase 3 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | January 24, 2013 | August 4, 2022 |
| NCT01855828 | Completed | Phase 2 | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | September 2013 | August 2018 |
| NCT01869192 | Completed | Phase 2 | Phase II Trial for Large ER-Negative Breast Cancers | March 5, 2003 | August 21, 2010 |
| NCT01966471 | Completed | Phase 3 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | January 31, 2014 | June 4, 2021 |
| NCT01985724 | Completed | Phase 3 | Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer | October 2007 | December 2013 |
| NCT02005783 | Completed | Phase 2 | Study of Danggui Buxue Decoction in Preventing Neutropenia | October 2013 | October 2015 |
| NCT02115204 | Completed | Phase 3 | 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF | June 2000 | August 2010 |
| NCT02125344 | Completed | Phase 3 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | December 2014 | January 30, 2017 |
| NCT02132949 | Completed | Phase 2 | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | July 14, 2014 | August 25, 2020 |
| NCT02214602 | Completed | Phase 4 | Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer | July 2014 | May 2017 |
| NCT02287129 | Completed | Phase 2 | Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction | December 5, 2014 | August 7, 2020 |
| NCT02307227 | Completed | Phase 2 | Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors | April 2006 | April 2014 |
| NCT02324088 | Completed | Phase 3 | Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer | October 2000 | January 2015 |
| NCT02395640 | Completed | Phase 3 | The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer | March 2015 | February 23, 2021 |
| NCT02400567 | Completed | Phase 2 | Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women | January 2015 | September 2020 |
| NCT02450058 | Completed | Phase 3 | Adjuvant FEC Versus EP in Breast Cancer (MIG5) | November 1996 | May 2012 |
| NCT02549677 | Completed | Phase 4 | Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer | October 2015 | March 2020 |
| NCT02682693 | Completed | Phase 2 | Denosumab as an add-on Neoadjuvant Treatment (GeparX) | February 13, 2017 | December 31, 2020 |
| NCT02685059 | Completed | Phase 2 | Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer | June 2016 | March 2018 |
| NCT02742051 | Completed | Phase 2 | A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer | June 2016 | March 14, 2020 |
| NCT02846428 | Completed | Phase 2 | To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer | March 2004 | December 2011 |
| NCT03013504 | Completed | Phase 3 | A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | February 19, 2018 | January 13, 2022 |
| NCT03272477 | Completed | Phase 2 | Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients | October 5, 2017 | March 4, 2024 |
| NCT03289819 | Completed | Phase 2 | Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC | March 23, 2018 | January 22, 2021 |
| NCT03356860 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. | April 13, 2017 | December 31, 2023 |
| NCT03556358 | Completed | Phase 3 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | June 28, 2018 | February 4, 2021 |
| NCT04031703 | Completed | Phase 3 | Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN) | January 1, 2011 | April 20, 2016 |
| NCT04127019 | Completed | Phase 3 | Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) | June 1, 2010 | June 15, 2017 |
| NCT04224922 | Completed | Phase 2 | Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer | May 2015 | May 2017 |
| NCT04659551 | Completed | Phase 2 | Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients | October 5, 2017 | May 25, 2020 |
| NCT06309732 | Completed | Phase 2 | GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT) | July 2006 | January 2014 |
| NCT05678933 | Enrolling by invitation | Phase 3 | AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH | January 1, 2023 | December 1, 2029 |
| NCT05287308 | Not yet recruiting | N/A | Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | March 2022 | September 2027 |
| NCT05491694 | Not yet recruiting | Phase 2 | To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer | September 1, 2022 | December 30, 2024 |
| NCT06291064 | Not yet recruiting | Phase 2 | Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer | June 2024 | June 2032 |
| NCT05887726 | Not yet recruiting | Phase 2 | Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors | August 1, 2023 | August 1, 2025 |
| NCT06227065 | Not yet recruiting | Phase 2 | Precise Neoadjuvant Chemoresection of Low Grade NMIBC | October 2024 | October 2029 |
| NCT05131893 | Not yet recruiting | Neoadjuvant Treatment of Breast Cancer | March 2022 | December 2031 | |
| NCT06404463 | Not yet recruiting | Phase 2 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer | May 6, 2024 | November 6, 2030 |
| NCT05983094 | Not yet recruiting | Phase 2 | Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | September 1, 2023 | September 1, 2027 |
| NCT05900206 | Recruiting | Phase 2 | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | October 26, 2023 | April 30, 2032 |
| NCT05901428 | Recruiting | Phase 3 | TCb vs EC-T in High Risk ER+/HER2- Breast Cancer | June 1, 2023 | June 2028 |
| NCT05883852 | Recruiting | Phase 3 | EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer | June 7, 2023 | July 1, 2031 |
| NCT05420454 | Recruiting | Phase 4 | A Study for the Neoadjuvant Treatment of Breast Cancer | July 10, 2022 | December 20, 2027 |
| NCT05420467 | Recruiting | Phase 4 | A Study for the Adjuvant Treatment of Breast Cancer | July 10, 2022 | December 20, 2027 |
| NCT05447702 | Recruiting | Phase 2 | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | November 1, 2022 | December 31, 2026 |
| NCT05472896 | Recruiting | Phase 3 | TACE With Dicycloplatin(TP21) in Unresectable HCC | June 9, 2022 | June 30, 2024 |
| NCT05582499 | Recruiting | Phase 1/Phase 2 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | November 1, 2022 | September 2025 |
| NCT05656079 | Recruiting | N/A | To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study | July 1, 2021 | September 2025 |
| NCT05681728 | Recruiting | Phase 2 | A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer | February 1, 2022 | June 1, 2024 |
| NCT02627248 | Recruiting | Phase 4 | Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | October 2015 | October 2025 |
| NCT05978648 | Recruiting | Phase 2 | Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy | September 20, 2023 | December 31, 2027 |
| NCT05981014 | Recruiting | Phase 1/Phase 2 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | August 1, 2023 | May 31, 2035 |
| NCT03277924 | Recruiting | Phase 1/Phase 2 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas | May 31, 2017 | June 30, 2025 |
| NCT03286634 | Recruiting | Phase 2 | ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | April 18, 2017 | March 31, 2033 |
| NCT06112379 | Recruiting | Phase 3 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | November 14, 2023 | August 28, 2030 |
| NCT06121570 | Recruiting | Phase 1 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | November 1, 2023 | August 31, 2031 |
| NCT06140966 | Recruiting | Phase 2 | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | October 20, 2023 | October 20, 2027 |
| NCT03876886 | Recruiting | Phase 3 | The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency | February 22, 2019 | December 2024 |
| NCT04067037 | Recruiting | Phase 2 | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma | August 26, 2019 | December 31, 2024 |
| NCT04193059 | Recruiting | Phase 3 | Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer | August 1, 2018 | July 2024 |
| NCT04296175 | Recruiting | Phase 3 | Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) | March 5, 2020 | June 2025 |
| NCT04433156 | Recruiting | Phase 2 | VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma | April 22, 2020 | April 22, 2025 |
| NCT04576143 | Recruiting | Phase 2/Phase 3 | Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer | September 20, 2020 | September 20, 2027 |
| NCT06389006 | Recruiting | Phase 2 | To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer | April 29, 2024 | December 31, 2026 |
| NCT04668365 | Recruiting | Phase 2 | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma | December 25, 2020 | December 25, 2025 |
| NCT04738188 | Recruiting | N/A | Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria; | March 18, 2020 | December 2025 |
| NCT04872985 | Recruiting | Phase 2 | Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial | April 20, 2021 | December 31, 2028 |
| NCT04877821 | Recruiting | Phase 2 | The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC | September 15, 2021 | December 31, 2025 |
| NCT04899570 | Recruiting | Phase 2 | Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma | April 1, 2021 | April 1, 2025 |
| NCT01740271 | Recruiting | Phase 2 | A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients | December 2012 | June 2025 |
| NCT05024734 | Recruiting | Phase 2 | Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids | November 17, 2022 | November 16, 2026 |
| NCT05033808 | Recruiting | Phase 2 | Epirubicin for the Treatment of Sepsis & Septic Shock | October 19, 2022 | December 2024 |
| NCT02897050 | Suspended | Phase 2 | Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer | September 2016 | September 2024 |
| NCT00193024 | Terminated | Phase 2 | Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer | September 2001 | October 2004 |
| NCT03894007 | Terminated | Phase 2 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | May 23, 2019 | June 30, 2021 |
| NCT01985841 | Terminated | Phase 2 | Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer | October 2011 | April 2015 |
| NCT00625898 | Terminated | Phase 3 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab | April 2008 | July 2014 |
| NCT00176488 | Terminated | Phase 2 | Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | June 2003 | October 2009 |
| NCT00162812 | Terminated | Phase 2 | Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin | January 2003 | April 2009 |
| NCT00756470 | Terminated | Phase 2 | Phase II Neoadjuvant in Inflammatory Breast Cancer | October 2008 | October 2013 |
| NCT00954512 | Terminated | Phase 1/Phase 2 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | September 25, 2009 | June 7, 2011 |
| NCT01779050 | Terminated | Phase 2 | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | December 19, 2013 | September 1, 2021 |
| NCT00431795 | Terminated | Phase 2 | Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer | June 2003 | June 2012 |
| NCT01830270 | Terminated | Phase 2 | Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer | May 2011 | July 2016 |
| NCT02076594 | Terminated | Phase 3 | Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer | January 2013 | December 31, 2018 |
| NCT01167738 | Terminated | Phase 2 | Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer | July 2010 | April 2015 |
| NCT01220128 | Terminated | Phase 2 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | April 11, 2011 | November 14, 2014 |
| NCT01929811 | Terminated | Phase 2 | NeoMET Study in Neoadjuvant Treatment of Breast Cancer | October 2013 | June 2020 |
| NCT00130936 | Terminated | Phase 1/Phase 2 | Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates | October 2005 | November 2007 |
| NCT01690325 | Terminated | Phase 2 | Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) | September 2012 | November 2016 |
| NCT01697072 | Terminated | Phase 3 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | October 2012 | August 2015 |
| NCT03273595 | Unknown status | Phase 2 | Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer | July 2016 | December 2019 |
| NCT04498793 | Unknown status | Phase 2 | Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer | September 2020 | December 2022 |
| NCT04771871 | Unknown status | Phase 2 | MicroRNA Profiles in Triple Negative Breast Cancer | November 29, 2021 | August 2023 |
| NCT03647280 | Unknown status | N/A | The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer | December 1, 2018 | September 30, 2020 |
| NCT00218205 | Unknown status | Phase 2 | A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer | July 2002 | June 2006 |
| NCT00957125 | Unknown status | Phase 2 | A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early | September 2008 | November 2016 |
| NCT03668418 | Unknown status | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | June 1, 2018 | May 31, 2022 | |
| NCT03349177 | Unknown status | Phase 2/Phase 3 | Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy | November 27, 2017 | November 27, 2019 |
| NCT02115152 | Unknown status | Phase 2 | Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer | June 2014 | |
| NCT05053386 | Unknown status | N/A | Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma | October 2021 | April 2023 |
| NCT00450203 | Unknown status | Phase 2/Phase 3 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | October 2007 | December 2017 |
| NCT04676997 | Unknown status | Phase 2 | Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | May 20, 2020 | February 28, 2024 |
| NCT01428414 | Unknown status | Phase 2 | Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer | August 2011 | February 2015 |
| NCT04717531 | Unknown status | Phase 2 | Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | June 3, 2021 | May 31, 2024 |
| NCT02760953 | Unknown status | N/A | TURBt With Adjuvant Cryoablation to Treat Bladder Cancer | October 19, 2017 | December 31, 2018 |
| NCT01503905 | Unknown status | N/A | Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients | December 2011 | December 2021 |
| NCT02871869 | Unknown status | Phase 2/Phase 3 | Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma | September 2016 | December 2021 |
| NCT02879513 | Unknown status | Phase 3 | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | January 2014 | December 2022 |
| NCT05121350 | Unknown status | Phase 3 | A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma | March 2022 | June 2024 |
| NCT00499603 | Unknown status | Phase 2 | Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | July 2007 | April 2017 |
| NCT00531973 | Unknown status | Phase 4 | A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging | January 2007 | December 2009 |
| NCT02949258 | Unknown status | Phase 2 | Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer | January 2017 | January 2021 |
| NCT02694224 | Unknown status | Phase 2 | Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients | April 2016 | December 2018 |
| NCT02971345 | Unknown status | Phase 3 | Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus | January 2017 | November 2020 |
| NCT02987244 | Unknown status | Phase 1/Phase 2 | Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma | March 2016 | March 2023 |
| NCT02631499 | Unknown status | Phase 4 | Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation | December 2015 | December 2019 |
| NCT03373708 | Unknown status | Phase 2/Phase 3 | Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer | December 20, 2017 | December 20, 2019 |
| NCT02177552 | Unknown status | Phase 2 | Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma | June 2014 | November 2019 |
| NCT03756090 | Unknown status | N/A | The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer | December 1, 2018 | November 30, 2020 |
| NCT03123770 | Unknown status | Phase 4 | Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients | December 2016 | December 2021 |
| NCT02510781 | Unknown status | Phase 2 | A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs | January 2015 | December 2017 |
| NCT00843934 | Unknown status | Phase 2/Phase 3 | Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma | March 2009 | February 2015 |
| NCT04290793 | Unknown status | Phase 2/Phase 3 | Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | March 1, 2020 | March 1, 2024 |
| NCT01159236 | Withdrawn | N/A | Molecular Triaging of Newly Diagnosed Breast Cancer | September 2010 | |
| NCT01327521 | Withdrawn | Phase 3 | Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma | February 2011 | |
| NCT01205217 | Withdrawn | Phase 2 | Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer | December 2010 | December 2010 |